Avanos Medical, INC.: directors' dealings · United States · SEC (Form 4)

About Avanos Medical, INC.

Avanos Medical, Inc. (ticker: AVNS) is a U.S.-based medical technology company listed on the NYSE in the United States. The company focuses on specialized medical devices that support enteral feeding, pain management, and post-operative recovery. Its investment profile is that of a niche medtech player: Avanos is less about broad, commoditized hospital supplies and more about clinically oriented, differentiated products used in workflows where ease of use, safety, and patient outcomes matter. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1606498/000110465925024289/tm253661d2_ars.pdf?utm_source=openai)) Avanos traces its modern corporate history to the 2014 spin-off of Halyard Health and rebranded as Avanos Medical in 2018. The company is headquartered in Alpharetta, Georgia, giving it a clear operational base in the southeastern United States while maintaining an international footprint. Avanos presents itself as a global business, with commercial reach across North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. ([avanos.com](https://avanos.com/about-avanos/?utm_source=openai)) The business is organized around two main franchises: Specialty Nutrition Systems and Pain Management & Recovery. Specialty Nutrition Systems covers enteral feeding and medication preparation/delivery products used across the continuum of care, from NICU and pediatric settings through adult long-term care. Pain Management & Recovery provides non-opioid solutions for chronic and post-surgical pain, including radiofrequency ablation, cryocompression, and ambulatory pain pumps. Key brand names include MIC-KEY, CORPAK, COOLIEF, ambIT, and GAME READY, which are central to the company’s clinical positioning. ([avanos.com](https://avanos.com/our-brands/?utm_source=openai)) From a competitive standpoint, Avanos occupies a specialized segment of the medtech market, competing against larger device manufacturers but differentiating through clinical specialization, targeted product innovation, and strong support for healthcare professionals and patients. The company also emphasizes manufacturing integration and product training/support, which can be important in procedures that require reliability and consistent performance. ([avanos.com](https://avanos.com/wp-content/uploads/2025/04/Avanos-2024-Corporate-Citizenship-Report-vF.pdf?utm_source=openai)) Recent strategic developments suggest a portfolio refinement strategy. In 2023, Avanos agreed to acquire Diros Technology to strengthen its radiofrequency pain-treatment offering, adding technology designed to complement the COOLIEF platform. In the same year, it divested its Respiratory Health business to SunMed, reinforcing a narrower focus on the franchises it believes offer better strategic fit. For investors, AVNS therefore remains a NYSE-listed U.S. healthcare company with a focused product set, international distribution, and a strategy centered on portfolio optimization rather than aggressive breadth expansion. ([avanos.com](https://avanos.com/news/avanos-medical-inc-announces-agreement-to-acquire-diros-technology-inc/?utm_source=openai))